Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations.

Immunotherapy of mice with preexisting cancers with heat shock protein preparations derived from autologous cancer resulted in retarded progression of the primary cancer, a reduced metastatic load, and prolongation of life-span. Treatment with heat shock protein preparations derived from cancers other than the autologous cancer did not provide significant protection. Spontaneous cancers (lung cancer and melanoma), chemically induced cancers (fibrosarcoma and colon carcinoma), and an ultraviolet radiation-induced spindle cell carcinoma were tested, and the results support the efficacy of autologous cancer-derived heat shock protein-peptide complexes in immunotherapy of cancers without the need to identify specific tumor antigenic epitopes.

[1]  P. Srivastava,et al.  Peptide-binding heat shock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation. , 1993, Advances in cancer research.

[2]  P. Bruggen,et al.  Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.

[3]  Lieping Chen,et al.  Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected. , 1995, Journal of immunology.

[4]  P. Srivastava,et al.  Heat shock protein vaccines against cancer. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[5]  M. A. Basombrío.  Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene. , 1970, Cancer research.

[6]  Michael Feldman,et al.  Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides , 1995, Nature Medicine.

[7]  P. Srivastava,et al.  Purification of immunogenic heat shock protein 70-peptide complexes by ADP-affinity chromatography. , 1997, Journal of immunological methods.

[8]  P. Srivastava,et al.  A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. , 1995, Science.

[9]  C. Stock,et al.  Studies in a tumor spectrum. III. The effect of phosphoramides on the growth of a variety of mouse and rat tumors. , 1955, Cancer research.

[10]  D. Pardoll.  A new look for the 1990s , 1994, Nature.

[11]  D. Hanahan,et al.  Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy , 1997, The Journal of experimental medicine.

[12]  P. Srivastava,et al.  Heat shock protein 70-associated peptides elicit specific cancer immunity , 1993, The Journal of experimental medicine.

[13]  J. Wilschut,et al.  Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides. , 1997, Immunology letters.

[14]  P. Srivastava,et al.  Do human cancers express shared protective antigens? or the necessity of remembrance of things past. , 1996, Seminars in immunology.

[15]  P. Srivastava,et al.  Tumor rejection antigens of chemically induced sarcomas of inbred mice. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[16]  E. Román,et al.  Synthetic peptides non‐covalently bound to bacterial hsp 70 elicit peptide‐specific T‐cell responses in vivo , 1996, Immunology.

[17]  E. Jaffee,et al.  The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[18]  P. Srivastava,et al.  Molecular heterogeneity of tumor rejection antigen/heat shock protein GP96 , 1995, International journal of cancer.

[19]  A. Globerson,et al.  ANTIGENIC SPECIFICITY OF BENZO(A)PYRENE-INDUCED SARCOMAS. , 1964, Journal of the National Cancer Institute.

[20]  H. Rammensee,et al.  Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96 , 1995, The Journal of experimental medicine.

[21]  Z. Li,et al.  Tumor rejection antigen gp96/grp94 is an ATPase: implications for protein folding and antigen presentation. , 1993, The EMBO journal.

[22]  M. Miller,et al.  Regulation of murine macrophage IL-12 production. Activation of macrophages in vivo, restimulation in vitro, and modulation by other cytokines. , 1996, Journal of immunology.

[23]  F. Koning,et al.  Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Srivastava,et al.  Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Pramod K Srivastava,et al.  The serologically unique cell surface antigen of zajdela ascitic hepatoma is also its tumor‐associated transplantation antigen , 1984, International journal of cancer.